A Study of the Long-Term Safety of ABT-089 for Subjects With Mild-to-Moderate Alzheimer's Disease Who Participated in the M06-876 Study.

Trial Profile

A Study of the Long-Term Safety of ABT-089 for Subjects With Mild-to-Moderate Alzheimer's Disease Who Participated in the M06-876 Study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2016

At a glance

  • Drugs Pozanicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 01 Sep 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 01 Sep 2011 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual patient number (58) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top